Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCEIS and Fecal Calprotectin to Predict Reaction to Corticosteroids in Acute Severe Ulcerative Colitis
NCT02922374Phase 2Unknown
- Sponsor
- Jinling Hospital
- Start
- Jan 2013
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of corticosteroids in Colitis, sponsored by Jinling Hospital. Primary endpoints: Stool frequency at 3 days and C-reactive protein at 3 days. Status: unknown.
02
Drugs
corticosteroids
03
Conditions
Colitis
Beyond the preview
Go deeper on NCT02922374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922374.